Share Email Print

Proceedings Paper

Photodynamic therapy using aminolevulinic acid (ALA)
Author(s): Ruediger Bachor; Ella Dumbravia Reich; Kurt Miller; Richard E. Hautmann
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Photodynamic therapy (PDT) is a treatment modality for a variety of cancers. Since no ideal photosensitizer is available yet, new photosensitizers are being sought. A new concept of PDT is the use of endogenous photosensitizers. ALA is a metabolite in heme synthesis. It is a precursor of protoporphyrin IX, a potent photosensitizer. After administration of ALA it is transformed by the cells to protoporphyrin IX. The goal of our study was to examine dark toxicity of ALA and its phototoxic potential in two different human cell lines.

Paper Details

Date Published: 1 March 1994
PDF: 9 pages
Proc. SPIE 2078, Photodynamic Therapy of Cancer, (1 March 1994); doi: 10.1117/12.168677
Show Author Affiliations
Ruediger Bachor, Univ. Ulm (Germany)
Ella Dumbravia Reich, Univ. Ulm (Germany)
Kurt Miller, Univ. Ulm (Germany)
Richard E. Hautmann, Univ. Ulm (Germany)

Published in SPIE Proceedings Vol. 2078:
Photodynamic Therapy of Cancer
Giulio Jori; Johan Moan; Willem M. Star, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?